epirubicin has been researched along with Neoplasm Metastasis in 261 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (13.79) | 18.7374 |
| 1990's | 82 (31.42) | 18.2507 |
| 2000's | 99 (37.93) | 29.6817 |
| 2010's | 41 (15.71) | 24.3611 |
| 2020's | 3 (1.15) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Da, LT; Guo, F; Hong, X; Lin, M; Song, K; Xu, W; Zhang, S; Zhang, X | 1 |
| Bartnik, E; Bielecka, ZF; Brodaczewska, KK; Czarnecka, AM; Maliszewska-Olejniczak, K; Porta, C; Szczylik, C | 1 |
| Cheng, X; Li, Y; Tian, Y | 1 |
| Al-Batran, SE; Ganguli, A; Lordick, F; Morlock, R; Sahin, U; Türeci, Ö | 1 |
| Liu, Y; Shang, D; Song, B | 1 |
| Liu, S; Qin, Y; Song, X; Sun, Z; Wang, Y; Yang, J; Yu, K; Zhang, S; Zhou, X | 1 |
| Fang, Z; Hao, Y; Hu, X; Li, J; Li, L; Liu, X; Tan, M; Wang, Q; Wu, C; Wu, Q; Wu, Y; Xu, J; Yang, X; Yang, Z; Zhao, J | 1 |
| Charlson, J | 1 |
| Cai, FY; Fu, M; Gong, XQ; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Tang, W; Yao, XM | 1 |
| D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM | 1 |
| Chang, DY; Chen, WW; Cheng, AL; Hsu, C; Huang, CS; Huang, SM; Lin, CH; Lin, MH; Lu, YS | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Bostnavaron, M; Campone, M; Chan, S; Conte, PF; Nguyen, L; Santoro, A | 1 |
| Bilici, A | 1 |
| Cihan, YB | 1 |
| Li, J; Li, X; Liu, H; Liu, M; Wang, J; Xu, J; Yang, H; Zhang, Y | 1 |
| Doshi, S; Gisleskog, PO; Loh, E; Oliner, KS; Perez Ruixo, JJ; Zhang, Y; Zhu, M | 1 |
| Ashmawy, AM; Bahhnassy, A; El-Bastawisy, A; Ismail, MF; Mohanad, M; Shaarawy, S; Zekri, AR | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G | 1 |
| Liu, L; Wang, J; Yan, B | 1 |
| Accortanzo, V; Adami, F; Bighin, C; Bruzzi, P; Castiglione, F; Cavazzini, G; Conte, P; Danese, S; Del Mastro, L; Durando, A; Garrone, O; Landucci, E; Levaggi, A; Michelotti, A; Miglietta, L; Pastorino, S; Piras, M; Pronzato, P; Scotto, T | 1 |
| Barbolosi, D; Ciccolini, J; Freyer, G; Iliadis, A; Meille, C | 1 |
| Barbolosi, D; Freyer, G; Guitton, J; Hénin, E; Iliadis, A; Meille, C; You, B | 1 |
| Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, Y; Yu, S; Yu, YY; Zhao, NQ; Zhuang, RY | 1 |
| Chen, J; Chen, X; Li, N; Liu, Y; Sun, Q; Wang, B | 1 |
| Aaltonen, K; Aittomäki, K; Bartek, J; Bartkova, J; Blomqvist, C; Eskelinen, M; Fagerholm, R; Heikkilä, P; Hofstetter, B; Holli, K; Kallioniemi, A; Kataja, V; Kilpivaara, O; Kosma, VM; Lukas, J; Mannermaa, A; Nevanlinna, H; Syrjäkoski, K; Tommiska, J; Uusitupa, M; von Smitten, K; Vrtel, R | 1 |
| Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G | 1 |
| Bosso, G; Ceste, M; de Conciliis, E; Ferrero, G; Ferro, S; Giaretto, L; Lanfranco, C; Manfredi, R; Miglietta, L; Milanese, S; Parello, G; Simoni, C; Testore, F | 1 |
| Choi, IK; Kim, AR; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Park, KH; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Bruzzi, P; Carella, C; Conte, P; De Tursi, M; Frassoldati, A; Gennari, A; Iacobelli, S; Orlandini, C; Ricevuto, E | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Izzo, F; Nisticò, C; Sperduti, I; Terzoli, E; Tropea, F; Vaccaro, V | 1 |
| Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Petrillo, A; Rinaldo, M; Siani, C | 1 |
| Arena, MG; Di Lauro, L; Fattoruso, SI; Giacinti, L; Giannarelli, D; Lopez, M; Sergi, D | 1 |
| Dreisbach, L; Kristedja, T; Kurtin, S; Mahadevan, D; Obregon, Y; Von Hoff, DD; Williams, D | 1 |
| Rihova, B | 1 |
| Bidard, FC; Brain, E; de Cremoux, P; Delaloge, S; Giachetti, S; Marty, M; Mathiot, C; Pierga, JY | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Blohmer, JU; Friese, K; Hilfrich, J; Kleine-Tebbe, A; Koelbl, H; Kuemmel, S; Lichtenegger, W; Morack, G; Schmid, P; Sommer, H; Wischnewsky, MB | 1 |
| Ashley, S; Cunningham, D; Okines, AF | 1 |
| Kanzaki, M; Maeda, M; Matsumoto, K; Miyoshi, S; Takano, Y; Teshima, S; Wakita, T; Yoshinouchi, S | 1 |
| Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T | 1 |
| Bordin, F; De Marco, F; Di Nicola, S; Lanzetta, G; Rozzi, A; Salerno, M | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E; Thomas, R | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Danso-Appiah, A; Eastwood, A; Norman, G; Palmer, S; Rice, S; Spackman, E; Stirk, L; Suh, D | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Ping, SY; Wu, CL; Yu, CP; Yu, DS | 1 |
| Anan, K; Arime, I; Chijiiwa, K; Fujii, T; Hara, S; Imamura, S; Inoue, H; Ishikawa, E; Mitsuyama, S; Nishimura, R; Ohchi, T; Ohkido, M; Ohno, S; Oikawa, T; Shimada, K; Tamura, K; Tanaka, M; Taniguchi, H; Yano, H | 1 |
| Cottura, E; Dalenc, F; De Benedictis, E; Deslandres, M; Gianni, L; Gladieff, L; Govi, S; Locatelli, A; Messina, M; Roché, H; Zambetti, M | 1 |
| Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R | 1 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Correale, P; Fiaschi, AI; Francini, G; Manganelli, A; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Salvestrini, F | 1 |
| Aitini, E; Cantore, M; Guadagni, S; Rabbi, C; Zamagni, D | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Bauduceau, O; Bernard, O; Ceccaldi, B; Dourhte, LM; Hervé, R; Le Moulec, S | 1 |
| Caris, CT; Carpentier, P; de Bruin, MJ; Debruyne, FM; Fernandez de Moral, P; van Andel, G; Wils, J; Witjes, JA; Witjes, WP | 1 |
| Nabholtz, JM | 1 |
| Blomqvist, C; Elomaa, I; Joensuu, H | 1 |
| Bouaziz, M; Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Jlidi, R; Toumi, N | 1 |
| Almanza, C; Ballesteros, P; Belón, J; Casal, J; Castellanos, J; Frau, A; Galán, A; Lizón, J; Llorca, C; Lorenzo, A; Machengs, I; Méndez, M; Morales, S; Moreno-Nogueira, JA; Oltra, A; Ramos, M | 1 |
| Andersen, J; Ejlertsen, B; Hansen, S; Højris, I; Kjaer, M; Kristensen, B; Mouridsen, HT; Møholt, K; Rose, C | 1 |
| Alba, E; Alvarez, I; Arcusa, A; Balil, A; Barnadas, A; Batista, N; Camps, C; Checa, T; Curto, J; De La Haba, J; Frau, A; Jara, C; Lopez-Vega, JM; Martin, M; Oltra, A; Pelegri, A; Perez-Carrion, R; Pico, C; Rodriguez-Lescure, A; Tres, A | 1 |
| Benevolo, M; Botti, C; Buglioni, S; Cognetti, F; Del Nonno, F; Di Filippo, F; Giannarelli, D; Mottolese, M; Natali, PG; Papaldo, P; Venanzi, FM; Vici, P | 1 |
| Di Costanzo, G; Garrone, O; Granetto, C; Mercuri, M; Merlano, M; Numico, G; Occelli, M; Principe, E; Rattazzi, PD | 1 |
| Blohmer, JU; du Bois, A; Ebert, A; Eidtmann, H; Emons, G; Harbeck, N; Heilman, V; Höffken, K; Jackisch, C; Kuhn, W; Langer, B; Lück, HJ; Meerpohl, HG; Muscholl, M; Pauschinger, M; Reichardt, P; Thomssen, Ch; Untch, M; Wallwiener, D; Wiese, W | 1 |
| Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Cunningham, D; Dickson, JL | 1 |
| Andersen, J; Ejlertsen, B; Kjaer, M; Langkjer, ST; Mouridsen, HT; Sjöström, J | 1 |
| Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Azarnia, N; Chan, S; Davidson, N; Erdkamp, F; Juozaityte, E; Lee, LW; Pluzanska, A | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Brausi, M; Carpentier, P; de Reijke, TM; Hall, RR; Kurth, KH; Landsoght, KE; Sylvester, RJ; van de Beek, K | 1 |
| Advani, SH; Doval, DC; Ermisch, S; Feher, O; Jassem, J; Khoo, KS; Miller, MA; Morack, G; Roychowdhury, D; Vodvarka, P; von Minckwitz, G | 1 |
| Brandely, M; Coleman, R; Delozier, T; Jones, A; Kreuser, ED; Longerey, B; Mross, K; Serin, D; Verrill, M | 1 |
| Arena, MG; Belli, F; Carpano, S; Di Lauro, L; Giannarelli, D; Lopez, M; Paoletti, G | 1 |
| Oberlin, O; Orbach, D; Quintana, E; Rey, A; Sanchez de Toledo, J; Stevens, MC; Terrier-Lacombe, MJ; van Unnik, A | 1 |
| Adami, E; Carlini, P; Cognetti, F; De Marco, S; Fariello, AM; Felici, A; Gamucci, T; Gelibter, A; Moscetti, L; Pollera, CF; Ruggeri, EM; Sperduti, I | 1 |
| Bang, YJ; Ham, HS; Hong, YS; Im, SA; Im, YH; Kim, KW; Kim, SB; Kim, TY; Kim, WK; Lee, J; Lee, KE; Lee, KH; Lee, MA; Lee, MH; Lee, NS; Lee, SN; Park, HS; Park, YH; Seo, JH; Song, HS | 1 |
| Barletta, E; Bruni, GS; D'Angelo, R; Daniele, B; Ferrari, E; Fiore, F; Formato, R; Iaffaioli, RV; Ottaiano, A; Pignata, S; Tortoriello, A; Turitto, G | 1 |
| Alamanis, C; Bougas, D; Dimitrakopoulos, A; Giannopoulos, A; Kopterides, P; Kopteridis, P; Kosmas, C; Mitropoulos, D; Skopelitis, H; Stravodimos, K; Tsavaris, N | 1 |
| Cameron, DA; Carmichael, J; Howell, A; Jones, AL; Langley, RE; Parmar, M; Qian, W; Uscinska, B | 1 |
| Glaser, A; Picton, SV; Prestwich, RJ; Taylor, RE | 1 |
| Koulentianos, E; Polyzos, A; Sfikakis, P; Tzianoumis, L | 1 |
| Alexopoulos, A; Papacharalambous, A; Rigatos, G; Scartsilas, C; Stavrakakis, J; Stavrinidis, E | 1 |
| Gorbunov, VA; Kopychev, IuE; Kubyshkin, SI; Seriakov, AP; Smolin, AV; Sukirko, VA; Zav'ialov, MS | 1 |
| Bisogno, G; Casale, F; Cecchetto, G; De Salvo, G; Di Martino, M; Di Tullio, MT; Donfrancesco, A; Donofrio, V; Ferrari, A; Indolfi, P; Martone, A | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Maio, E; de Matteis, A; Di Maio, M; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Rossi, E | 1 |
| Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Karray, H; Khanfir, A | 1 |
| Aguggini, S; Allevi, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Bruzzi, P; Campo, L; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M; Wigfield, SM | 1 |
| Bozec, L; Campone, M; Diéras, V; Espié, M; Fumoleau, P; Kayitalire, L; Petit, T; Pouillart, P; Pujade-Lauraine, E; Serin, D; Viens, P | 1 |
| Aboagye, EO; Al-Nahhas, A; Coombes, RC; Kenny, L; Shousha, S; Vigushin, DM | 1 |
| Seemann, MD | 1 |
| Bao, YH; Fang, JW; Huang, S; Mou, BH; Shen, P; Shi, MG; Xiong, PJ; Xu, N; Zhang, CX; Zhong, XL | 1 |
| Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Khanfir, A | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E | 1 |
| Bamias, A; Giannopoulos, A; Gourgoulis, G; Mountzios, G; Papaiakovou, EE; Rodolakis, A; Vlahos, G; Voulgaris, Z | 1 |
| Bachelot, T; Battista, C; Biron, P; Curé, H; Delozier, T; Durand, M; Fargeot, P; Monnot, F; Poiget, E; Roché, H; Spaeth, D; Tanguy, ML | 1 |
| Alvarez, A; Dirix, L; Dumez, H; Latz, J; Melemed, A; Oliveira, CT; Paridaens, R; Prové, A; Simms, L; Wildiers, H | 1 |
| Du, H; Gu, W; Hong, X; Leaw, J; Qian, Y; Wang, B; Yin, J; Zhu, X | 1 |
| Armand, JP; Cappelaere, P; Hurteloup, P; Mathé, G | 1 |
| Cervek, J; Kolarić, K; Potrebica, V | 1 |
| Bramwell, V; Bruntsch, U; Cavalli, F; Decoster, G; Dombernowsky, P; Høst, H; Renard, G; Rozencweig, M; ten Bokkel Huinink, W; Van Glabbeke, M | 1 |
| Jones, WG; Mattsson, W | 1 |
| Berman, E; Casper, ES; Howard, J; Wittes, RE | 1 |
| Cartei, G; Ferrazzi, E; Fiorentino, MV; Fornasiero, A; Nicoletto, O; Pappagallo, GL; Refatti, F; Vinante, O | 1 |
| Gandara, DR; Gribble, M; Kohler, M; Meyers, FJ; Mitchell, E; Porzig, KJ; Torti, FM; Volberding, P | 1 |
| Bae, E; Fosså, SD; Lien, HH; Wik, B | 1 |
| Carpano, S; Conti, F; Di Lauro, L; Giannarelli, D; Gionfra, T; Lopez, M; Paoletti, G; Pignatti, F; Vici, P | 1 |
| Brausi, M; de Mulder, PH; Droz, JP; Fosså, SD; Jones, WG; Lentz, MA; Pawinski, A; van Glabbeke, M | 1 |
| Hansen, F; Skovsgaard, T; Stenbygaard, L | 1 |
| Konecny, G; Nestle-Krämling, C; Untch, M | 1 |
| Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S | 1 |
| Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R | 1 |
| Kouri, M; Kuitunen, T; Nyandoto, P; Pyrhönen, S | 1 |
| Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D | 1 |
| Agostara, B; Cariello, S; Colucci, G; Durini, E; Gebbia, V; Giotta, F; Pacilio, G; Pezzella, G; Romito, S; Testa, A | 1 |
| Bucci, L; Caponigro, F; Di Martino, N; Facchini, G; Fei, L; Iaffaioli, RV; Mantovani, G; Santangelo, M; Tortoriello, A | 1 |
| Adenis, A | 1 |
| Biakhov, MIu; Buianov, SS; Dobrovol'skaia, NIu; Voznyĭ, EK | 1 |
| Chacón, I; Colmenarejo, A; Espinosa, E; Feliu, J; García-Girón, C; Garrido, P; González-Barón, M; Ordóñez, A; Zamora, P | 1 |
| Higashida, T; Koishi, Y; Koyama, H; Masuyama, M; Miyata, K; Mugitani, T; Takeuchi, K; Tanaka, H; Taniguchi, H; Yamaguchi, T | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 2 |
| Botti, C; Cercato, MC; Cognetti, F; Del Bianco, S; Ferraresi, V; Sacchi, I; Scinto, AF; Tonachella, R | 1 |
| Ammon, A; Eggeling, B; Kesztyüs, T; Kreienberg, R; Marschner, N; Räth, U; Ruffert, K; Schütte, M; Souchon, R; Voigtmann, R | 1 |
| Biron, P; Catimel, G; Chauvin, F; Clável, M; Guastalla, JP; Rebattu, P | 1 |
| Burghouts, JT; Conroy, T; de Graeff, A; Fickers, MM; Lalisang, FM; Paillot, B; Wagener, DJ; Wils, J | 1 |
| Ashley, S; Jones, AL; O'Brien, ME; Ramage, F; Robertshaw, H; Smith, IE; Talbot, D; Walsh, G | 1 |
| Amadori, D; Baldini, E; Brema, F; Gardin, G; Monzeglio, C; Naso, C; Pastorino, G; Pronzato, P; Rosso, R; Rubagotti, A | 1 |
| Bohn, C; Edler, L; Goebel, M; Heidemann, E; Hossfeld, DK; Jonat, W; Mross, K; Queisser, W | 1 |
| Blomqvist, C; Elomaa, I; Helle, L; Hietanen, P; Nevasaari, K; Rissanen, P | 1 |
| Allum, WH; Baum, M; Bonnefoi, H; Ebbs, S; O'Brien, ME; Powles, TJ; Seymour, MT; Smith, IE | 1 |
| Barbanti, G; De Capua, B; De Lauretis, A; Francini, G; Frediani, B; Manganelli, A; Mondillo, S; Petrioli, R; Salvestrini, F | 1 |
| Campioni, N; Cognetti, F; Ferraresi, V; Giannarelli, D; Piarulli, L; Sacchi, I; Scinto, AF; Tonachella, R | 1 |
| Awada, A; Bartholomeus, S; Bruning, P; Paridaens, R; Piccart, MJ; Schornagel, JH; Thomas, J; Tomiak, E; Wildiers, J; Witteveen, PO | 1 |
| Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E | 1 |
| Fujishiro, Y; Fuse, H; Katayama, T; Muraishi, Y | 1 |
| Holmes, FA | 1 |
| Chambers, EJ; Cook, AM; Rees, GJ | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Amadori, A; Amadori, D; Amaducci, L; Giunchi, DC; Maltoni, R; Nanni, O; Saragoni, A; Silvestrini, R; Vio, A; Volpi, A | 1 |
| Bonneterre, J; Catimel, G; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Spielmann, M; Tubiana-Hulin, M | 1 |
| Diergarten, K; du Bois, A; Hecker, D; Jänicke, F; Konecny, G; Kühnle, H; Lindner, C; Lisboa, BW; Lück, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Brugger, W; Engelhardt, R; Fetscher, S; Frommhold, H; Hasse, J; Kanz, L; Lange, W; Mertelsmann, R; Wenger, M | 1 |
| Andersson, M; Ejlertsen, B; Mouridsen, HT; Pedersen, D; Pfeiffer, P; Rose, C | 1 |
| Hubmer, G; Lehnert, M; Pummer, K; Stettner, H | 1 |
| Evans, TR; Gogas, H; Lofts, FJ; Mansi, JL; Millard, FJ; Wilson, R | 1 |
| Diergarten, K; du Bois, A; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 2 |
| Fuechsel, G; Kettner, E; Köhler, U; Olbricht, SS; Richter, B; Ridwelski, K | 1 |
| Carmichael, J; Hutchinson, T; Jones, A | 1 |
| Dicato, M; Duhem, C; Kleiber, K; Ries, F | 1 |
| Cariello, S; Colucci, G; Galetta, D; Gebbia, N; Gebbia, V; Riccardi, F | 1 |
| Borsellino, N; Colucci, G; Gebbia, N; Gebbia, V; Giotta, F; Latteri, MA; Milia, V; Testa, A; Valdesi, M | 1 |
| Ashley, S; Chang, JC; Gregory, RK; Powles, TJ | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Andrulis, I; Blackstein, M; Franssen, E; Fraser, RA; Goss, PE; Hedley, D; Hill, W; Kates, R; Knight, S; Myers, R; Oldfield, S; Pritchard, KI; Roche, K; Trudeau, M; Warner, E; Warr, D; Webster, S | 1 |
| Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET | 1 |
| Chen, YM; Lin, WC; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW; Wu, MF | 1 |
| Hehenwarter, W; Kornek, G; Krainer, M; Maca, S; Nirnberger, G; Ploszczynski, M; Samonigg, H; Scheithauer, W; Schüller, J; Stierer, M; Stöger, H; Vavra, N; Wirth, M; Zielinski, CC | 1 |
| Borden, EC; Green, M; Haller, DG; Marsh, JC; Rosenthal, MA; Wiernik, P | 1 |
| Dombernowsky, P; Hansen, J; Jensen, BV; Nielsen, D; Ryberg, M; Skovsgaard, T | 1 |
| Pagani, O | 1 |
| Bastert, G; Goldschmidt, H; Haas, R; Hohaus, S; Huober, J; Martin, S; Meyer, A; Schneeweiss, A; Wallwiener, D; Wittmann, G | 1 |
| Aiba, K; Horikoshi, N; Ito, Y; Mizunuma, N; Mukaiyama, T; Ogawa, M; Takahashi, S | 1 |
| Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E | 1 |
| Borsellino, N; Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Lelli, G; Lopez, M; Maiello, E; Testa, A | 1 |
| de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Bewick, M; Chadderton, T; Conlon, M; Glück, S; Lafrenie, R; Morris, D; Stewart, D | 1 |
| Bareck, E; Depisch, D; Funovics, J; Hejna, M; Kornek, GV; Kovats, E; Lang, F; Miholic, J; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Cottu, PH; Espie, M; Extra, JM; Marty, M; Mignot, L; Morvan, F; Zelek, L | 1 |
| Dunst, J; Tanner, J | 1 |
| Goa, K; Holm, K; Ormrod, D; Spencer, C | 1 |
| Bláha, M; Filip, S; Mericka, P; Podzimek, K; Vanásek, J; Vávrová, J | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Awasthy, BS; Gairola, M; Julka, PK; Rath, GK; Sharma, DN | 1 |
| Bearman, SI | 1 |
| Blijham, GH; Erdkamp, FL; Hillen, HF; Lalisang, RI; Nortier, JW; Schouten, HC; Voest, EE; Wals, J; Wils, JA | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Algeri, R; Barsanti, G; Bastiani, P; Fallai, C; Guarneri, A; Marzano, S; Neri, B; Pacini, P; Rinaldini, M; Tucci, E | 1 |
| Schiøler, V; Sölétormos, G | 1 |
| Capasso, I; Carteni, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Frezza, P; Lapenta, L; Maiorino, L; Rivellini, F; Thomas, R | 1 |
| Carrasco, J; de Sande, G; Esteban, E; Fernández, JL; Fra, J; Lacave, AJ; Modollel, A; Muñiz, I; Palacio, I; Puertas, J; Sala, M; Vieitez, JM | 1 |
| Ackland, SP; Anton, A; Breitbach, GP; Colajori, E; Delfino, C; Efremidis, A; Ezzat, A; Fittipaldo, A; Kolaric, K; Lopez, M; Tursi, JM; Viaro, D | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Antman, KH | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Bafaloukos, D; Briassoulis, E; Dimopoulos, AM; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Papadimitriou, C; Pavlidis, N; Razis, E; Samantas, E | 1 |
| Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L | 1 |
| Bertuzzi, A; Capri, G; Cresta, S; Giani, A; Gianni, L; Grasselli, G; Locatelli, A; Materazzo, C; Perotti, A; Spreafico, C; Tarenzi, E; Valagussa, P; Viganò, L | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Fountzilas, G; Razis, ED | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| De Filippis, S; Piccinini, M; Pompili, P; Rea, S; Recchia, F; Rosselli, M; Saggio, G | 1 |
| Airoldi, M; Bumma, C; De Crescenzo, A; Gabriele, AM; Marchionatti, S; Pedani, F; Rosti, G; Succo, G | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Baselga, J | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Fischer, L; Foss, HD; Koch, HC; Korfel, A; Thiel, E | 1 |
| Dunst, J; Haensgen, G | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Conte, PF; Gennari, A; Landucci, E; Orlandini, C | 1 |
| Levine, M | 1 |
| Amodio, A; Belli, F; Brandi, M; Colucci, G; Conti, F; Durini, E; Gebbia, N; Gebbia, V; Giannarelli, D; Giotta, F; Lopez, M; Pezzella, G; Pisconti, S; Valerio, MR; Vici, P | 1 |
| Zielinski, CC | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Jassem, J; Kánitz, E; Kaplan, E; Kolaric, K; Mechl, Z; Pawlicki, M; Ringwald, G; Rolski, J; Schoket, Z; Vukas, D | 1 |
| Bengtsson, NO; Eksborg, S; Elfsson, B; Hardell, L; Sjödin, M | 1 |
| Kouri, MO; Pyrhönen, SO | 1 |
| Bub, P; Eisenberger, F; Rüther, U; Schmidt, A | 1 |
| Cold, S; Pfeiffer, P; Rose, C | 1 |
| Haase, KD; Heckmann, M; Lange, OF; Leyendecker, R; Scheef, W; Urban, G; Zegners, G | 1 |
| abdel Wareth, A; Dardir, MD; el Khodari, A; el Mawla, NG; el Zawahry, H; Gaafar, R; Habboubi, N; Hamza, MR; Khaled, H | 1 |
| Coombes, RC; Glees, J; Rawson, NS; Topham, C; Woods, EM | 1 |
| Gebbia, N; Gebbia, V; Meli, M; Palmeri, S; Rausa, L; Russo, A | 1 |
| Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA | 1 |
| Jungi, WF; Senn, HJ; Thürlimann, B | 1 |
| Ghavamzadeh, A | 1 |
| Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B | 1 |
| Beretta, G; Fraschini, P; Labianca, R; Locatelli, C; Luporini, G; Tabiadon, D | 1 |
| Edler, L; Flechtner, H; Heim, ME; Kabelitz, K; Massner, B; Queisser, W | 1 |
| Blum, RH; Lafleur, F; Molinaro, P | 1 |
| Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Michlmayr, G; Samonigg, H; Schiller, L; Sevelda, P; Steger, G | 1 |
| Papadopoulos, I; Wand, H | 1 |
| Carpano, S; Conti, EM; Di Lauro, L; Lopez, M; Papaldo, P; Vici, P | 1 |
| Bäuerle, K; Bub, P; Eisenberger, F; Jipp, P; Rassweiler, J; Rüther, U | 1 |
| Camaggi, CM; Pannuti, F; Strocchi, E | 1 |
| Abad-Esteve, A; Fernandez, C; Monras, P; Moreno, I; Morera, J; Ribas-Mundo, M; Rosell, R; Ruiz, J | 1 |
| Beyer, JH; Emrich, D; Holtkamp, W; Kneba, M; Luig, H; Marschner, N; Nagel, GA; Rauschning, W; Unger, C; Wander, HE | 1 |
| Ammon, A; Beyer, JH; Emrich, D; Holtkamp, W; Kneba, M; Luig, H; Marschner, N; Nagel, GA; Rauschning, W; Unger, C | 1 |
| Arnold, H; Flechtner, H; Fritsch, H; Fritz, M; Fritze, D; Heim, ME; Henss, H; Herrmann, R; Queisser, W; Trux, FA | 1 |
| Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M | 1 |
| Diedrich, K; Heuer, J; Krebs, D; Oberheuser, F; Schulz, BO; Werner, A | 1 |
| Hausmaninger, H; Lehnert, M | 1 |
| Amadori, D; Conte, PF; Falcone, A; Gardin, G; Gentilini, P; Nicolin, A; Pronzato, P; Rosso, R; Rubagotti, A; Sismondi, P | 1 |
| Bono, AV; De Pauw, M; Fosså, SD; Jones, WG; Klijn, JG; Sylvester, R | 1 |
| Kolarić, K; Potrebica, V; Stanovnik, M | 1 |
| Christmann, D | 1 |
| Hartlapp, JH | 1 |
| Armand, PP; Cappelaere, P; Hurteloup, P; Keiling, R | 1 |
| Alama, A; Amadori, D; Conte, PF; Demicheli, R; Gardin, G; Gentilini, P; Jacomuzzi, A; Lionetto, R; Pronzato, P; Rubagotti, A | 1 |
| Gribble, M; Hannigan, JF; Lewis, B; Meyers, FJ; Mitchell, E; Torti, FM; William, L | 1 |
| Bosl, GJ; Howard, J; Magee, MJ; Wittes, RE | 1 |
| Hurteloup, P; Iliadis, A; Mauriac, L; Nguyen-Ngoc, T; Robert, J; Vrignaud, P | 1 |
19 review(s) available for epirubicin and Neoplasm Metastasis
| Article | Year |
|---|---|
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Epirubicin; Humans; Ifosfamide; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms | 2018 |
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Docetaxel; Epirubicin; Fluorouracil; Humans; Medical Oncology; Neoplasm Metastasis; Palliative Care; Pyrimidines; Quality of Life; Receptor, ErbB-2; Stomach Neoplasms; Taxoids; Trastuzumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; In Situ Hybridization, Fluorescence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasm Metastasis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Systemic treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Epirubicin; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Preoperative Care; Stomach Neoplasms; Treatment Outcome | 2004 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Fluorouracil; Humans; Ifosfamide; Neoplasm Metastasis; Paclitaxel | 1996 |
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 1996 |
Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.
Topics: Adjuvants, Pharmaceutic; Antibiotics, Antineoplastic; Breast Neoplasms; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Quality of Life | 1999 |
Randomized trials of high dose chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Thiotepa | 2001 |
Paclitaxel: epirubicin in metastatic breast cancer--a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Safety; Single-Blind Method; Survival Analysis; Trastuzumab; Treatment Outcome | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Mitomycin; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Uterine Cervical Neoplasms | 2001 |
Role of epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
Epirubicin in breast cancer: present and future.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Neoplasm Metastasis; Receptor, ErbB-2 | 2000 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplasm Metastasis; Vincristine | 1992 |
161 trial(s) available for epirubicin and Neoplasm Metastasis
| Article | Year |
|---|---|
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Claudins; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Patient Reported Outcome Measures; Progression-Free Survival; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2021 |
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Vinblastine; Young Adult | 2014 |
Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Stomach Neoplasms | 2015 |
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2015 |
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2016 |
Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Models, Theoretical; Neoplasm Metastasis; Taxoids | 2016 |
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2009 |
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2009 |
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume; Survival Rate; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2009 |
Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Epirubicin; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Rate; Taxoids | 2009 |
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Celecoxib; Cell Separation; Cyclophosphamide; Docetaxel; Early Detection of Cancer; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Young Adult | 2010 |
Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Urologic Neoplasms | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids | 2011 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids | 2012 |
A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Dose-Response Relationship, Drug; Epirubicin; Epothilones; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2012 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Weekly epirubicin in patients with hormone-resistant prostate cancer.
Topics: Aged; Androgens; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pain; Prostatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival; Treatment Outcome | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Drug Administration Schedule; Epirubicin; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Quality of Life | 2003 |
Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; France; Humans; Infusions, Intravenous; Italy; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
Combined epirubicin and vinorelbine as first-line therapy in metastatic breast cancer: a pilot study performed by the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Pilot Projects; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Interactions; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause; Tamoxifen | 2004 |
A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Genes, erbB-2; Heart Diseases; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prospective Studies; Trastuzumab | 2004 |
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left | 2004 |
Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2004 |
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2004 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life | 2004 |
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Disease Progression; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Multiple Primary; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2005 |
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.
Topics: Aged; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2005 |
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2005 |
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Humans; Ifosfamide; Infant; Infant, Newborn; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rhabdomyosarcoma; Sarcoma; Survival Analysis; Teniposide; Vincristine | 2005 |
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Stomach Neoplasms; Time Factors | 2006 |
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Statistics, Nonparametric; Survival Analysis; United Kingdom | 2005 |
[Combined (chemo-radiation) treatment of patients with nasopharyngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Radiation Dosage | 2005 |
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids | 2006 |
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Endpoint Determination; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2007 |
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins | 2007 |
Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Analysis; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2008 |
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Glutamates; Guanine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pemetrexed; Treatment Outcome | 2007 |
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2008 |
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Carubicin; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Follow-Up Studies; Heart Diseases; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Random Allocation; Vomiting | 1984 |
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Survival Rate | 1995 |
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.
Topics: Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Drug Resistance, Neoplasm; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies | 1995 |
Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Mitomycin; Neoplasm Metastasis; Palliative Care; Time Factors | 1994 |
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Palliative Care; Stomach Neoplasms | 1994 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Palliative Care; Stomach Neoplasms; Vitamin A; Vitamin E | 1995 |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Neutropenia | 1995 |
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Life Tables; Mastectomy, Radical; Menopause; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Treatment Outcome | 1995 |
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indazoles; Interferon alpha-2; Interferon-alpha; Menopause; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Premenopause; Recombinant Proteins | 1995 |
Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Stomach Neoplasms; Survival Rate | 1995 |
[Recurrence and survival rate of advanced gastric cancer after preoperative EAP-II intra-arterial infusion therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Humans; Infusions, Intra-Arterial; Neoplasm Metastasis; Neoplasm Recurrence, Local; Preoperative Care; Stomach Neoplasms; Survival Rate | 1994 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome | 1994 |
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate | 1994 |
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 1993 |
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis | 1994 |
Stimulation of human breast cancer in vivo. Experimental findings and clinical results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Diethylstilbestrol; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Staging | 1993 |
Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Rate; Verapamil | 1993 |
Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 1993 |
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis | 1996 |
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Recombinant Proteins; Remission Induction | 1995 |
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Europe; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Pilot Projects; Recombinant Proteins; Remission Induction | 1995 |
Epirubicin and ifosfamide in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Humans; Ifosfamide; Neoplasm Metastasis; Survival Rate | 1996 |
Comparison of mitozantrone and epirubicin in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Epirubicin; Heart Diseases; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 1996 |
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Cyclophosphamide; Epirubicin; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Small Cell; Cardiovascular Diseases; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonectomy; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 1997 |
Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Tamoxifen | 1996 |
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Flutamide; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Software; Treatment Outcome | 1997 |
Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outpatients; Survival Rate | 1997 |
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Humans; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quality of Life | 1997 |
Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Vinblastine; Vinorelbine | 1997 |
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1997 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Humans; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prospective Studies; Survival Rate; Vincristine | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Topics: Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Verapamil | 1998 |
Phase II study of paclitaxel in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Stomach Neoplasms; Survival Analysis; Thrombocytopenia; Time Factors | 1998 |
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Epirubicin; Female; Fluorouracil; Humans; Ifosfamide; Leucovorin; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Salvage Therapy | 1998 |
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1998 |
Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colorectal Neoplasms; Epirubicin; Female; Head and Neck Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Thiotepa | 1998 |
Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
Topics: Adult; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1999 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Mitoxantrone; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Thiotepa | 1999 |
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Stomach Neoplasms; Survival Analysis | 1999 |
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxacin; Costs and Cost Analysis; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fever; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Length of Stay; Leukopenia; Methotrexate; Middle Aged; Neoplasm Metastasis; Netherlands; Prospective Studies; Recombinant Proteins | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Survival Rate; Time Factors | 1999 |
High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1999 |
[Polychemotherapy versus monotherapy in metastatic breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Epirubicin; Female; Humans; Mitomycin; Neoplasm Metastasis; Quality of Life; Treatment Outcome | 1999 |
The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cance
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukocyte Count; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Recombinant Proteins | 1999 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Ventricular Function, Left | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2000 |
Description of a computer program to assess cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen information during monitoring of metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoembryonic Antigen; Epirubicin; Female; Humans; Mucin-1; Neoplasm Metastasis; Software; Tissue Polypeptide Antigen | 2000 |
Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2000 |
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Spain; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intravenous; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2001 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Greece; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis | 2001 |
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2001 |
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Epirubicin; Female; Humans; Myocardium; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Analysis | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Vinblastine; Vinorelbine | 2002 |
Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Drug Evaluation; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1992 |
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms | 1992 |
Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Humans; Ifosfamide; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Palliative Care; Prospective Studies; Radiotherapy | 1990 |
A phase II study of epirubicin in breast cancer.
Topics: Adult; Breast Neoplasms; Drug Evaluation; Echocardiography; Electrocardiography; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Myocardium; Neoplasm Metastasis; Radiography | 1991 |
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Follow-Up Studies; Humans; Mitomycin; Mitomycins; Neoplasm Metastasis; Pancreatic Neoplasms | 1991 |
Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Remission Induction | 1991 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Imidazoles; Metoclopramide; Neoplasm Metastasis; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluation; Epirubicin; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Multicenter Studies as Topic; Neoplasm Metastasis; Stomach Neoplasms | 1989 |
A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Epirubicin; Fluorouracil; Humans; Neoplasm Metastasis; Random Allocation; Rectal Neoplasms; Sigmoid Neoplasms; Time Factors | 1989 |
Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Germany, West; Humans; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Metastasis; Prednimustine; Randomized Controlled Trials as Topic; Survival Rate; Vindesine | 1989 |
[Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Erythrocyte Count; Hemoglobinometry; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Peptides; Platelet Count; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tissue Extracts; Vomiting | 1989 |
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Nausea; Neoplasm Metastasis; Prospective Studies; Random Allocation; Vomiting | 1988 |
5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis | 1989 |
A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4'-epidoxorubicin, and VP-16 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Podophyllotoxin; Random Allocation | 1987 |
Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Random Allocation; Vindesine | 1988 |
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis | 1987 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Fluorouracil; Heart Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Sigmoid Neoplasms; Stomach Neoplasms | 1986 |
[French FAC vs FEC study in advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis | 1986 |
Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Random Allocation; Statistics as Topic | 1987 |
Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Glucuronates; Half-Life; Humans; Kinetics; Liver Neoplasms; Middle Aged; Neoplasm Metastasis | 1985 |
81 other study(ies) available for epirubicin and Neoplasm Metastasis
| Article | Year |
|---|---|
Legumain inhibitor prevents breast cancer bone metastasis by attenuating osteoclast differentiation and function.
Topics: Animals; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Epirubicin; Female; Mice; Neoplasm Metastasis; Osteoclasts | 2023 |
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance.
Topics: Biomarkers, Tumor; Biomimetics; Carcinoma, Renal Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Serum-Free; Doxycycline; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Laminin; Neoplasm Metastasis; Neoplastic Stem Cells; Phenotype; Spheroids, Cellular; Sunitinib | 2019 |
Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Desmoplastic Small Round Cell Tumor; Epirubicin; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oncogene Proteins, Fusion; Pyridines; RNA-Binding Protein EWS; Treatment Outcome; Vincristine; WT1 Proteins | 2020 |
Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; RNA, Messenger; Transforming Growth Factor beta; Up-Regulation; Urologic Neoplasms; Urothelium | 2018 |
Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Topics: Adipocytes; Adult; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CCL5; Coculture Techniques; Emodin; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Apoptosis; Cell Line, Tumor; Databases, Genetic; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; G1 Phase Cell Cycle Checkpoints; Hepatocyte Nuclear Factor 1-alpha; Humans; Kaplan-Meier Estimate; Lymphoid Enhancer-Binding Factor 1; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Urinary Bladder Neoplasms | 2018 |
Development of R
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Drug Liberation; Epirubicin; Humans; Lipid Bilayers; Liposomes; Lung Neoplasms; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2019 |
Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Taxoids | 2013 |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: a comparative study of the efficacy of anthracyclines and non-anthracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Palliative Care; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Survival Rate | 2013 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Body Mass Index; Breast Neoplasms; Breast Neoplasms, Male; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Middle Aged; Neoplasm Metastasis; Obesity; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Thinness; Treatment Outcome | 2014 |
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Epirubicin; ErbB Receptors; Female; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2014 |
Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, IGF Type 1; Transforming Growth Factor beta1; Treatment Outcome; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2015 |
Chemotherapy promotes tumour cell hybridization in vivo.
Topics: Animals; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Hybrid Cells; Mice; Neoplasm Metastasis; Prognosis; Xenograft Model Antitumor Assays | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Preoperative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
CYR61 suppresses growth of human malignant melanoma.
Topics: Animals; Antibodies, Monoclonal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine-Rich Protein 61; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Melanoma; Melanoma, Experimental; Mice; Neoplasm Metastasis; Skin Neoplasms | 2016 |
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Death; Combined Modality Therapy; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Genotype; Homozygote; Humans; Models, Biological; NAD(P)H Dehydrogenase (Quinone); Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2008 |
Platinum-based chemotherapy in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Vinblastine | 2008 |
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Epirubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Life Expectancy; Middle Aged; Neoplasm Metastasis; Razoxane; Retrospective Studies | 2008 |
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Preoperative Care; Treatment Outcome | 2009 |
Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates.
Topics: Acrylamides; Adult; Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Epirubicin; Female; Hemangiosarcoma; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Immunologic Factors; Middle Aged; Neoplasm Metastasis; Polymethacrylic Acids; Quality of Life; Treatment Outcome | 2009 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Fluorouracil; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2010 |
[Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Taxoids; Trastuzumab | 2010 |
Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2010 |
Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Epirubicin; Female; Humans; Indoles; Mice; Neoplasm Metastasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
[Chemotherapy protocol with taxol increase survival by 31 percent].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
[Cylindroma of the trachea, a rate tumor with unusual evolution].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Adenoid Cystic; Cisplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Radiography, Thoracic; Radiotherapy Dosage; Taxoids; Tracheal Neoplasms; Treatment Outcome | 2003 |
Nasopharyngeal carcinoma in childhood and adolescence: analysis of a series of 32 patients treated with combined chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Quality of Life; Survival Analysis; Treatment Outcome | 2003 |
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Epirubicin; Fas Ligand Protein; fas Receptor; Female; Humans; Immunohistochemistry; Membrane Glycoproteins; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Phenotype; Prognosis; Proportional Hazards Models; Prospective Studies; Time Factors; Treatment Outcome | 2004 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
Fatal pneumonitis in children with metastatic rhabdomyosarcoma following whole lung radiotherapy and sequential epirubicin.
Topics: Antibiotics, Antineoplastic; Child; Child, Preschool; Combined Modality Therapy; Epirubicin; Fatal Outcome; Female; Humans; Lung; Lung Diseases, Interstitial; Male; Neoplasm Metastasis; Radiotherapy; Rhabdomyosarcoma | 2007 |
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; Humans; Leukopenia; Male; Mitomycin; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 1989 |
Second and third line chemotherapy in advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Vinblastine; Vincristine | 1989 |
Prognostic factors in pleuro-pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Combined Modality Therapy; Dactinomycin; Disease Progression; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pleural Neoplasms; Pneumonectomy; Prognosis; Pulmonary Blastoma; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Second-Look Surgery; Treatment Outcome; Vincristine | 2007 |
[Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Radiotherapy Dosage; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Disease-Free Survival; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Premenopause; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome | 2006 |
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Dideoxynucleosides; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Kinetics; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Treatment Outcome | 2007 |
Diagnostic value of PET/CT for predicting of neoadjuvant chemotherapy response.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Monitoring; Epirubicin; Female; Humans; Liver Neoplasms; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Ribs; Tomography, X-Ray Computed | 2007 |
Prognostic factors in metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Tunisia | 2007 |
Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Topotecan | 2008 |
Phase II clinical evaluation of 4'-epi-doxorubicin.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms | 1983 |
Phase-II clinical trial of 4'-epi-doxorubicin in metastatic solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms | 1983 |
Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Cell Count; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Humans; Menopause; Middle Aged; Neoplasm Metastasis; Time Factors | 1984 |
Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Time Factors | 1984 |
Phase II evaluation of 4'epi-doxorubicin in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms | 1984 |
Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Stereoisomerism | 1984 |
Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Epirubicin; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis | 1982 |
[Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Neoplasm Metastasis | 1993 |
[Etoposide, epirubicin and cisplatin (EEP) combination in metastatic cancers of the cardia and the stomach. Groupe de recherche en cancérologie du Nord (GRECNO)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Epirubicin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 1994 |
[Comparison of the effectiveness and toxicity of parenteral and oral vepesid in the treatment of disseminated breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Injections, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Time Factors | 1995 |
FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Stereoisomerism | 1994 |
Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Castration; Drug Resistance; Epirubicin; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate | 1996 |
Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Thymidine; Tumor Cells, Cultured | 1997 |
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Risk Factors; Time Factors | 1998 |
Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Transplantation, Autologous | 1999 |
Paclitaxel-epirubicin in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects | 1999 |
High-dose chemotherapy for breast cancer: we have not heard the final word.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; Risk Factors | 2000 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Transplantation, Autologous | 2001 |
Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cell Differentiation; Cisplatin; Combined Modality Therapy; Diphosphonates; Epirubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Lumbar Vertebrae; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Multiple Primary; Orchiectomy; Pamidronate; Remission Induction; Rhabdomyosarcoma; Seizures; Seminoma; Spinal Neoplasms; Teratoma; Testicular Neoplasms; Transplantation, Autologous | 2001 |
Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.
Topics: Adult; Aged; Body Weight; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Obesity; Remission Induction | 1992 |
Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Peptides; Sensitivity and Specificity; Tissue Polypeptide Antigen; Urinary Bladder Neoplasms; Vinblastine | 1992 |
Anthracycline-carboplatin combination in metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Organoplatinum Compounds | 1990 |
Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Fluorouracil; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Survival Rate | 1990 |
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epirubicin; Female; Humans; Ifosfamide; Neoplasm Metastasis; Sarcoma | 1990 |
Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care | 1987 |
[Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 1989 |
The role of pharmacokinetics in the clinical treatment of metastases.
Topics: Antineoplastic Agents; Doxorubicin; Epirubicin; Humans; Liver Neoplasms; Medroxyprogesterone; Medroxyprogesterone Acetate; Neoplasm Metastasis; Neoplasms; Tamoxifen | 1988 |
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Vindesine | 1988 |
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis | 1988 |
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug Evaluation; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms | 1987 |
[Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Tegafur; Thrombocytopenia | 1988 |
[Experiences with PAC and PEC polychemotherapy in the treatment of advanced and recurrent breast cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Lymph Node Excision; Mastectomy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 1988 |
European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
Topics: Aged; Carcinoma; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Epirubicin; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1987 |
[Epirubicin in combination chemotherapy of metastasized breast cancer (VEC) and advanced ovarian cancer (PEC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Ovarian Neoplasms; Vincristine | 1986 |
[Epirubicin--results in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Prognosis | 1986 |
Phase II trial of 4'-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study.
Topics: Adult; Aged; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Epirubicin; Humans; Leukocyte Count; Middle Aged; Neoplasm Metastasis; Platelet Count; Rectal Neoplasms | 1985 |
Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Doxorubicin; Drug Evaluation; Epirubicin; Female; Head and Neck Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Platelet Count | 1985 |